Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
Proteomics
|
April 27, 2005
Bacterial protein microarrays for identification of new potential diagnostic markers for Neisseria meningitidis infections
Sigrid Steller, Philipp Angenendt, Dolores J Cahill, et al.
Advances in Experimental Medicine and Biology
|
October 19, 2016
Detection and Quantification of KIT Mutations in ctDNA by Plasma Safe-SeqS
Johannes Fredebohm, Daniel H Mehnert, Ann-Kathrin Löber, et al.
Analytical Chemistry
|
April 1, 2004
Cell-free protein expression and functional assay in nanowell chip format
Philipp Angenendt, Lajos Nyarsik, Witold Szaflarski, et al.
Analytical Chemistry
|
May 18, 2004
Seeing better through a MIST: evaluation of monoclonal recombinant antibody fragments on microarrays
Philipp Angenendt, Jeannine Wilde, Gregor Kijanka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 3, 2011
Detection of tumor DNA at the margins of colorectal cancer liver metastasis
Matthias Holdhoff, Kerstin Schmidt, Frank Diehl, et al.
Science (New York, N.Y.)
|
August 8, 2009
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells
Jihye Yun, Carlo Rago, Ian Cheong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2012
Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood
Michaela J Higgins, Danijela Jelovac, Evan Barnathan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 10, 2016
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)
Chris Karlovich, Jonathan W Goldman, Jong-Mu Sun, et al.
Oncotarget
|
May 19, 2015
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
Filip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Oncotarget
|
September 26, 2015
Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
Filip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
Proteomics
|
April 27, 2005
Bacterial protein microarrays for identification of new potential diagnostic markers for Neisseria meningitidis infections
Sigrid Steller, Philipp Angenendt, Dolores J Cahill, et al.
Advances in Experimental Medicine and Biology
|
October 19, 2016
Detection and Quantification of KIT Mutations in ctDNA by Plasma Safe-SeqS
Johannes Fredebohm, Daniel H Mehnert, Ann-Kathrin Löber, et al.
Analytical Chemistry
|
April 1, 2004
Cell-free protein expression and functional assay in nanowell chip format
Philipp Angenendt, Lajos Nyarsik, Witold Szaflarski, et al.
Analytical Chemistry
|
May 18, 2004
Seeing better through a MIST: evaluation of monoclonal recombinant antibody fragments on microarrays
Philipp Angenendt, Jeannine Wilde, Gregor Kijanka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 3, 2011
Detection of tumor DNA at the margins of colorectal cancer liver metastasis
Matthias Holdhoff, Kerstin Schmidt, Frank Diehl, et al.
Science (New York, N.Y.)
|
August 8, 2009
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells
Jihye Yun, Carlo Rago, Ian Cheong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2012
Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood
Michaela J Higgins, Danijela Jelovac, Evan Barnathan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 10, 2016
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)
Chris Karlovich, Jonathan W Goldman, Jong-Mu Sun, et al.
Oncotarget
|
May 19, 2015
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
Filip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Oncotarget
|
September 26, 2015
Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
Filip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Page
of 3